Purpose {#S0001}
=======

Endometrial cancer is the most common malignancy of the female reproductive tract in developed countries. The highest incidence rates are in Western Europe and North America with world age standardized incidence per 100,000 being 11.2 and 16.4, respectively in 2008, compared to 1.9 in Western and Middle Africa and a world incidence of 8.2 \[[@CIT0001]\]. The incidence rises with increasing age and peaks in the sixth and seventh decade. Obesity is a well-recognized risk factor, increasing the risk of developing endometrial cancer three-fold. This specific relationship has been explained by alterations in hormone metabolism in obese women \[[@CIT0002]\]. Endometrial cancer incidence has slowly increased over recent years. In the Netherlands, the incidence has increased from nearly 1600 new cases per year at the beginning of the 21^st^ century to between 1800 and 1950 new cases per year in the last 5 years. The incidence in elderly patients (\> 85 years) is approximately 150 new cases per year, and in patients aged above 90 years it is 30 new cases per year \[[@CIT0003]\].

General principles for the treatment of endometrial cancer {#S0002}
==========================================================

The treatment of choice is surgery: total abdominal or laparoscopic hysterectomy with bilateral salpingo-oophorectomy (TAH/TLH/BSO). The necessity of systematic lymphadenectomy is subject to discussion. Two large randomized studies did not demonstrate survival nor recurrence rate benefit of lymph node dissection (LND), however, the investigated patient population included predominantly intermediate risk tumors \[[@CIT0004], [@CIT0005]\]. That is why in general LND is being performed in the case of high risk tumors: FIGO stage 1B grade 3 and higher. The Clinical, TNM, FIGO 2009, and surgical pathological staging of endometrial cancer are shown in [Table 1](#T0001){ref-type="table"}.

###### 

Staging of endometrial cancer

  -----------------------------------------------------------------------------------------------------------------------------
  Clinical   TNM             FIGO 2009   FIGO Corpus Uteri 2009
  ---------- --------------- ----------- --------------------------------------------------------------------------------------
  I          T1\             I\          Tumor confined to corpus uteri\
             T1a\            IA\         No or less than 50% myometrial invasion\
             T1b             IB          More than 50% myometrial invasion

  II         T2              II          Tumor invades cervical stroma, but does not extend beyond the uterus

  III        T3 and/or N1\   III\        Local and/or regional spread of the tumor\
             T3a\            IIIA\       Tumor invades the serosa and/or adnexae\
             T3b\            IIIB\       Vaginal and/or parametrial involvement\
             T1-3 N1         IIIC\       Metastases to pelvic and/or para-aortic lymph nodes\
                             IIIC~1~\    Positive pelvic nodes\
                             IIIC~2~     Positive para-aortic nodes with or without positive pelvic nodes

  IV         T4 and/or M1\   IV\         Tumor invades bladder and/or bowel mucosa, and/or distant metastases\
             T4\             IVa\        Invasion of bladder/bowel mucosa\
             T1-4NxM1        IVb         Distant metastases, including intra-abdominal metastases and/or inguinal lymph nodes
  -----------------------------------------------------------------------------------------------------------------------------

The role of adjuvant radiation therapy has been established as a result of a number of essential randomized trials \[[@CIT0006]--[@CIT0009]\]. Postoperative external beam pelvic radiotherapy (EBRT) remains indicated for high risk and advanced disease, whilst vaginal brachytherapy (VBT) achieves excellent vaginal control and survival, and recurrence rates are similar to EBRT. Therefore, VBT is the adjuvant treatment of choice for patients with high-intermediate risk disease \[[@CIT0010]--[@CIT0012]\]. Subsequently chemotherapy was added, based upon the results of two recent randomized studies, in which adding chemotherapy in high risk patients showed improvement of 5-year progression free survival from 69% to 78% \[[@CIT0013]\]. Current ongoing studies are further investigating this subject (PORTEC 3, GOG 249, GOG 258). The outcome of various randomized studies resulted in evidence based guidelines is illustrated in [Table 2](#T0002){ref-type="table"}. The reported 5-year survival rates are 80% for the whole population, 85-90% for stage I, 75-85% for stage II, 50-65% for stage III, and 20-25% for stage IV \[[@CIT0014]\]. Approximately 55% of patients present with early stage, low risk tumors with a relapse free survival rate of 95% after primary surgical treatment and for this population adjuvant treatment is not indicated \[[@CIT0015]\].

###### 

Treatment of endometroid type endometrial cancer according to Dutch guidelines 2011 \[[@CIT0011]\]

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  FIGO 2009          Grade      Age (years)       Surgery                                                  Adjuvant therapy
  ------------------ ---------- ----------------- -------------------------------------------------------- ------------------------------------------------------------------------------------------------
  IA                 1, 2       All               TAH/TLH + BSO                                            No

  3                  \< 60      TAH/TLH + BSO     No (unless LVSI^1^: vaginal brachytherapy)               

  3                  ≥ 60       TAH/TLH + BSO     No (unless myometrium invasion: vaginal brachytherapy)   

  IB                 1, 2       \< 60             TAH/TLH + BSO                                            No

  1, 2               ≥ 60       TAH/TLH + BSO     Vaginal brachytherapy                                    

  3                             TAH + BSO + LND   Vaginal brachytherapy ± chemotherapy                     

  II                 1, 2, 3    All               Radical hysterectomy + LND\                              ± Chemotherapy\
                                                  TAH + BSO                                                Combination of external beam radiotherapy and vaginal brachytherapy ± chemotherapy

  IIIA\              1, 2, 3    All               TAH + BSO, macroscopically radical                       External beam radiotherapy ± chemotherapy
  IIIB~parametial~                                                                                         

  IIIB~vagina~       1, 2, 3    Vagina            TAH + BSO, macroscopically nonradical\                   Combination of external beam radiotherapy and vaginal brachytherapy\
                                                  Irresectable                                             Combination of external beam radiotherapy and brachytherapy, possibly followed by hysterectomy

  IIIC~1~/IIIC~2~\   1, 2, 3\   All               TAH + BSO ± LND                                          External beam radiotherapy ± chemotherapy\
  IVA/IVB            1, 2, 3                                                                               Palliation
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

LVSI -- lymph vessel space invasion

Primary brachytherapy in endometrial cancer {#S0003}
===========================================

There is an increasing population of aging or morbidly obese patients who cannot undergo any form of anesthesia, and as a consequence, in whom surgery is considered too high a risk. For these patients, hormonal treatment (eg. Mirena) can offer a solution, however only temporarily. When the symptoms of the cancer recur, the patient is even older and more fragile or vulnerable. For this population radical radiotherapy provides a solution with a high cure rate, and is also indicated in patients with an irresectable tumor. In 1947, the role of primary radiotherapy in endometrial cancer had already been described by Heyman \[[@CIT0016]\]. Several authors have subsequently described their experience using radium and low dose rate (LDR) \[[@CIT0017]--[@CIT0023]\]. In recent years, high dose rate (HDR) treated patient populations were also reported \[[@CIT0024]--[@CIT0030]\]. Nowadays different types of HDR applicators are available: modified Heyman packing, one channel applicators, and rotte Y applicators.

The effectiveness of HDR based primary radiotherapy for endometrial carcinoma was demonstrated in the results of several single institution reports that documented a 5-year disease specific survival (DSS) of up to 80% \[[@CIT0024]--[@CIT0030]\]. Coon *et al*. described in 2008 a 5-year DSS of 87% for a population of 47 patients with stage 1 disease and above, using a combination of external beam radiation and brachytherapy with a Rotte applicator \[[@CIT0024]\]. Another significant population (*N* = 280) was described by the Vienna group, with slightly inferior results with a 5-year DSS of 76%. However, in this later study an inferior applicator, a vaginal cylinder with one single intrauterine device was used \[[@CIT0026]\]. After the introduction of the Heyman packing, improved results were seen: 16 patients in one study with a 4-year DSS of 100% \[[@CIT0027]\]. Modified Heyman packing (Norman Simon applicators) consists of long thin flexible tubes available with capsules of different sizes at their top for packing in the uterine fundus and horns. This allows adaptation to the individual anatomy of the uterine cavity. The number of tubes applied varies between 5 and 18, depending on the individual anatomy. This technique results in adequate, probably even optimal dose distribution in the uterine corpus \[[@CIT0031]\]. This Heyman approach demonstrates excellent results, however the packing can only be inserted under anesthesia and is therefore not suitable for the population described above, where anesthesia is contraindicated due to comorbidities. In [Table 3](#T0003){ref-type="table"} some chosen results of HDR brachytherapy as primary treatment of endometrial cancer are presented. The toxicity differs, depending upon whether external beam is a part of the treatment or brachytherapy alone is applied. In the image guided brachytherapy alone series, the acute and late toxicity rate is very low, around 10% and predominantly grade 1 and 2 \[[@CIT0023]--[@CIT0030]\].

###### 

HDR brachytherapy as primary treatment of endometrial cancer

  Reference                          Nr. patients   Applicator            Treatment    5 year DSS
  ---------------------------------- -------------- --------------------- ------------ ------------
  Knocke *et al*. \[[@CIT0026]\]     235            Single intrauterine   HDR ± EBRT   76%
  Weitmann *et al*. \[[@CIT0027]\]   16             Heyman packing        HDR          4-yr 100%
  Coon *et al*. \[[@CIT0024]\]       49             Y-shaped Rotte        HDR ± EBRT   87%

Primary brachytherapy treatment description based on own experiences {#S20004}
--------------------------------------------------------------------

The Arnhem Radiotherapy Institute (ARTI) is specialized in brachytherapy, including brachytherapy for inoperable endometrial cancer. In our institution, we chose the Y-shaped Rotte applicator for this treatment, which we have used since 1995 and have successfully treated a total of 20 patients. This applicator comes in 4 sizes and can be completed with an additional vaginal cylinder, if the vagina is considerd to be part of the clinical target volume (CTV). The optimal coverage of the uterus is obtained by choosing the most appropriate applicator size. The correct applicator size is confirmed during the preplannig stage, based on imaging, preferably made by MRI scan or diagnostic CT-scan. The Y Rotte applicator is easy to insert without anesthesia. If necessary, a low dose tranquilizer provides sufficient premedication. Unfortunately, the applicator is not MRI compatible and for definitive planning purposes a CT-scan is the only suitable imaging.

At ARTI we have recently observed an increase in the number of patients who are referred for this treatment. These patients are elderly, obese or both. As stated above, a common problem is their inability to undergo any form of anesthesia. Once it is decided that the patient is unfit for surgery, a work up it is necessary to establish the definitive radiation treatment. In order to do this, a pathology report is needed with information about the histological diagnosis and the differentiation grade (always present) of the tumor. CT-scan or MRI scan images are necessary to provide information about the tumor extension, specifically the depth of endometrial infiltration and extension of the tumor to adjacent organs, typically parametrium and vagina, and the lymph node status. Additionally, ultrasound of the vagina and endometrium provides information about the endometrial wall thickness and the depth of tumor infiltration.

The primary treatment choice is either brachytherapy alone or as a boost in combination with external beam. Generally, brachytherapy alone is considered for FIGO stage 1A and 1B grade 1 and 2. Once there are indications for lymph node treatment: high grade histology and evidence of extensive myometrial involvement on MRI (FIGO 1B grade 3 and higher), a combination of external beam and brachytherapy has to be considered. The external beam therapy, if applicable, encompasses the entire uterus and cervix, at least the upper half of the vagina and lymph nodes up to the bifurcation of the common iliacs. The planned dose is 46-50.4 Gy in 23-28 fractions. The set-up of the brachytherapy procedure minimizes immobilization of the patient. The treatment consists of multiple applicator insertions, on an outpatient basis. If brachytherapy alone is given at ARTI, the patient receives 6 fractions of 6 Gy. If brachytherapy is given as a boost, the patient receives 3 fractions of 7 Gy. The American Brachytherapy Society has published treatment guidelines in 2000 \[[@CIT0032]\] as cited below in [Tables 4](#T0004){ref-type="table"} and [5](#T0005){ref-type="table"}.

###### 

Suggested doses of HDR only for treatment of inoperable primary endometrial cancer \[[@CIT0032]\]

  Nr. of HDR fractions   HDR dose/fx[\*](#TF0001){ref-type="table-fn"} at 2 cm from midpoint of intrauterine sources   Equivalent dose for tumor effects   Equivalent dose (late effects with DRF[\*\*](#TF0002){ref-type="table-fn"})
  ---------------------- --------------------------------------------------------------------------------------------- ----------------------------------- -----------------------------------------------------------------------------
  4                      8.5 Gy at 2 cm                                                                                52.4                                42.6
  5                      7.3 Gy at 2 cm                                                                                52.6                                41.4
  6                      6.4 Gy at 2 cm                                                                                52.5                                40.3
  7                      5.7 Gy at 2 cm                                                                                52.2                                39.0

fx -- fraction

DRF -- dose reduction factor

###### 

Suggested doses of external beam + HDR for treatment of inoperable primary endometrial cancer \[[@CIT0032]\]

  EBRT (Gy) @ 1.8 Gy/fx   Nr. of HDR fractions   HDR dose/fx      Equivalent dose for tumor effects   Equivalent dose (late effects with DRF)
  ----------------------- ---------------------- ---------------- ----------------------------------- -----------------------------------------
  45                      2                      8.5 Gy at 2 cm   70.5                                64.5
  45                      3                      6.3 Gy at 2 cm   69.9                                62.8
  45                      4                      5.4 Gy at 2 cm   70.6                                62.5

The entire brachytherapy procedure takes place in the treatment room. The patient is positioned on the gynecological bed in lithotomy position. The uterus is carefully probed using a soft plastic dilator. The applicator (in the appropriate size) is inserted, packed in position and fixed with a soft bandage. This out patient procedure can only be performed if the cervix and vagina are not involved. Post-implant imaging CT-scan is obtained immediately, followed by contouring of the uterus (CTV), the tumor gross tumor volume (GTV), and organs at risk (OAR): bladder, rectum and sigmoid. Treatment plans are individualized for each patient. Nag *et al*. described a methodology for the planning procedure including specification and optimization points ([Fig. 1](#F0001){ref-type="fig"}) \[[@CIT0032]\]. Image guided treatment planning secures further optimization.

![A methodology for the planning procedure including specification and optimization points. The dose specification points are at a point 2 cm from the central axis at the midpoint along the uterine applicator. Additional optimization points are placed at 2 cm from the central axis of the tandem at its midpoint. The isodose is widened at the uterine fundus to account for the increased uterine width at the fundus](JCB-6-22587-g001){#F0001}

We perform our planning accordingly. The ARTI planning procedure is best illustrated by a series of images ([Figs. 2A](#F0002){ref-type="fig"}--[C](#F0002){ref-type="fig"}, [Figs. 3A](#F0003){ref-type="fig"}--[C](#F0003){ref-type="fig"} and [Figs. 4A](#F0004){ref-type="fig"}--[C](#F0004){ref-type="fig"}), demonstrating the consecutive steps: CT-scan, contouring and definitive isodose distribution in the coronal, sagittal, and transversal views.

![A) CT-scan with Rotte applicator in the coronal view: The green and red points in the applicator are possible source positions. B) Contouring in the coronal view. The blue, pink, purple, and yellow contour lines are uterus, bowel, sigmoid, and urinary bladder, respectively. C) Definitive isodose distribution in the coronal view. The red isodose line illustrates 100%](JCB-6-22587-g002){#F0002}

![A) CT scan with Rotte applicator in the sagittal view. The green and red points in the applicator are possible source positions. B) Contouring in the sagittal view. The blue, pink, purple, and yellow contour lines are uterus, bowel, sigmoid, and urinary bladder, respectively. C) Definitive isodose distribution in the sagittal view. The red isodose line illustrates 100%](JCB-6-22587-g003){#F0003}

![A) CT scan with Rotte applicator in the transversal view. B) Contouring in the transversal view. The blue, pink, purple, and yellow contour lines are uterus, bowel, sigmoid and urinary bladder respectively. C) Definitive isodose distribution in the transversal view. The red isodose line illustrates 100%](JCB-6-22587-g004){#F0004}

By using 3D treatment planning we ensure to enclose the GTV with 100% isodose and intend to enclose the CTV with an isodose, which is as high as possible, keeping in mind that for OAR we intend not to exceed a cumulative isoeffective dose of D2cc for rectum of 75 Gy and for bladder of 80-85 Gy.

Each treatment is preceeded by a CT-scan and individual planning. After the planning the patient treatment follows. When finished, the applicator is removed and the patient can return home. Altogether, the patient spends two to three hours in our institution. The treatment is well tolerated by the patient. Fifty percent of patients developed acute toxicity in the form of enteritis CTCAE v4 grade 1 or 2 due to external beam radiation treatment, and one patient delevoped grade 2 small bowel late toxicity.

Discussion {#S0005}
==========

Primary (image guided) brachytherapy based radiotherapy for endometrial cancer is an effective, well tolerated treatment approach. A multicenter study would help to develop and introduce a uniform protocol to achieve optimal results for this specific patient population. Future improvements of the applicator, in order to meet modern brachytherapy requirements, could include the development of an MRI compatible applicator, as image quality of the MRI is superior to CT. The GTV is almost never visible on CT, the discrimination of pelvic structures is seen much better on MRI, especially distinction between the uterus and the bowel and the scatter of the applicator could be eliminated. If CT were to be replaced by MRI, the delineations of all structures would be easier and the planning time could be significantly reduced, which would ultimately increase the patient comfort.

Conclusions {#S0006}
===========

Primary (image guided) brachytherapy in inoperable endometrial cancer is an effective, well tolerated treatment approach with outcomes comparable to surgery. This approach might be considered more frequent in elderly and obese patients of any age for whom surgery may be associated with an increased risk of serious morbidity or even mortality.
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